Pharmacokinetic/pharmacodynamic study of sitaoxacin (DU-6859a) in patients with respiratory tract infections mainly caused by caused by S. pneumoniae

Trial Profile

Pharmacokinetic/pharmacodynamic study of sitaoxacin (DU-6859a) in patients with respiratory tract infections mainly caused by caused by S. pneumoniae

Completed
Phase of Trial: Phase II

Latest Information Update: 05 Jun 2017

At a glance

  • Drugs Sitafloxacin (Primary)
  • Indications Bacterial infections; Respiratory tract infections
  • Focus Pharmacodynamics; Pharmacokinetics; Therapeutic Use
  • Most Recent Events

    • 05 Jun 2017 Pooled results of this and another phase III trial assessing clinical dosage, PK/PD parameters and safety of Sitafoloxacin, presented at the ASM Microbe 2017
    • 01 Jun 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top